Phase 1 Multiple Sclerosis Trial, Recruiting (NCT06999434)

Phase 1 Multiple Sclerosis Trial, Recruiting NCT06999434 Sponsor: Yale University Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT06999434 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years of age or older, but younger than 90
You must be able to understand the study information and agree to take part by signing a consent form
You must be in good general health

Who may not be able to join:

You are under 18 years of age
You are currently pregnant or breastfeeding
You have a serious ongoing illness or a medical condition that is not stable or well-controlled
You have certain pre-existing medical conditions, or you experience anxiety or panic in enclosed spaces (such as a scanner) (confirm with trial site)
You have had a significant amount of radiation exposure from research studies in the past 12 months (confirm with trial site)
You have a history of a bleeding disorder, or you are currently taking blood-thinning medication

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Georges El Fakhri, PhD, DABR, Yale University

Phone: +1 (203) 737-5278

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06999434

Sponsor: Yale University

Phase: Phase 1

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: +1 (203) 737-5278

More information: https://clinicaltrials.gov/study/NCT06999434

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years of age or older, but younger than 90
You must be able to understand the study information and agree to take part by signing a consent form
You must be in good general health

Who may not be able to join:

You are under 18 years of age
You are currently pregnant or breastfeeding
You have a serious ongoing illness or a medical condition that is not stable or well-controlled
You have certain pre-existing medical conditions, or you experience anxiety or panic in enclosed spaces (such as a scanner) (confirm with trial site)
You have had a significant amount of radiation exposure from research studies in the past 12 months (confirm with trial site)
You have a history of a bleeding disorder, or you are currently taking blood-thinning medication

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Yale University

Registry

ClinicalTrials.gov

Start date

5 May 2025

Est. completion

5 May 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Tracers volume of distribution (VT); Distribution volume ratio (DVR); Binding potential (BPND); Demyelination; Tau burden; Amyloid burden; Tracer rate constant; Associations between imaging modalities and biomarkers.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov